Do you have your own idea?
If you need elements of answer, we suggest reading the very exhaustive review by Musga Qureischi , Julia Mohr , Estibaliz Arellano , Sarah Elspeth Knudsen , Farrukh Vohidovn and Andoni Garitano published in the international review of cell and molecularbiology*.
in-vitro transcribed (IVT) mRNA is translated in the cytoplasm after transfection into cells, can encode virtually any target protein and has several advantages:
– Compared to DNA: it does not enter the nucleus, which avoids its integration into the genome and the risk for insertional mutagenesis
– Compared to recombinant proteins: its large-scale production is less complex
The review discusses the chemical modifications of IVT mRNA and highlights numerous preclinical and clinical applications including:
- Vaccines for cancer and infectiousdiseases
- Cancer immunotherapy
- Protein replacement
We at Lifency congratulate the authors on their very interesting contribution and support the scientific and medical communities in their continuous and sustained efforts to identify novel therapeutic solutions
*Qureischi M, Mohr J, Arellano-Viera E, Knudsen SE, Vohidov F, Garitano-Trojaola A. mRNA-based therapies: Preclinical and clinical applications. Int Rev Cell Mol Biol. 2022;372:1-54. doi: 10.1016/bs.ircmb.2022.04.007. Epub 2022 Jun 3. PMID: 36064262. pharmaceuticalindustry